Identification of the effect of multiple polymorphisms on the pharmacokinetics of Simvastatin and Simvastatin acid using a population-modeling approach

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 90-100

  Tsamandouras, N ^a   Dickinson, G ^b   Guo, Y ^b   Hall, S ^b   Rostami Hodjegan, A ^a,c   Galetin, A ^a   Aarons, L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ORGANIC ANION TRANSPORTER B; SIMVASTATIN; SIMVASTATIN ACID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG;

ABCG2 GENE; ARTICLE; ATTRIBUTABLE RISK; BODY WEIGHT; CYP3A4 GENE; CYP3A5 GENE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROLYSIS; DRUG TRANSFORMATION; ETHNICITY; FIRST PASS EFFECT; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; JAPANESE (PEOPLE); MONTE CARLO METHOD; MYOPATHY; POPULATION MODEL; PPARA GENE; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; SLCO2B1 GENE;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; RISK FACTORS; SIMVASTATIN;

EID: 84902776362     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.55     Document Type: Article

References (43)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s) Lancet 344, 1383-1389 (1994)
2. Goldstein, J.L. & Brown, M.S. Regulation of the mevalonate pathway. Nature 343, 425-430 (1990)
3. Mauro, V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24, 195-202 (1993)
4. Collins, R., Armitage, J., Parish, S., Sleight, P. & Peto, R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002)
5. Vickers, S., Duncan, C.A., Chen, I.W., Rosegay, A. & Duggan, D.E. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18, 138-145 (1990)
6. Prueksaritanont, T. et al. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm. Res. 22, 1101-1109 (2005)
7. Prueksaritanont, T. et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30, 505-512 (2002)
8. Prueksaritanont, T. et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25, 1191-1199 (1997)
9. Prueksaritanont, T., Ma, B. & Yu, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56, 120-124 (2003)
10. Vickers, S. et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18, 476-483 (1990)
11. Thompson, P.D., Clarkson, P. & Karas, R.H. Statin-Associated myopathy. JAMA 289, 1681-1690 (2003)
12. Wilke, R.A. et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC) The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012)
13. Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006)
14. Link, E. et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N. Engl. J. Med. 359, 789-799 (2008)
15. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011)
16. Elsby, R., Hilgendorf, C. & Fenner, K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: its not just about OATP1B1. Clin. Pharmacol. Ther. 92, 584-598 (2012)
17. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010)
18. Elens, L. et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21, 861-866 (2011)
19. Kim, K.A., Park, P.W., Lee, O.J., Kang, D.K. & Park, J.Y. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47, 87-93 (2007)
20. Keskitalo, J.E., Pasanen, M.K., Neuvonen, P.J. & Niemi, M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10, 1617-1624 (2009)
21. Keskitalo, J.E., Kurkinen, K.J., Neuvoneni, P.J. & Niemi, M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther. 84, 457-461 (2008)
22. Kim, J. et al. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin. Pharmacol. Toxicol. 109, 156-163 (2011)
23. Son, H., Lee, D., Lim, L.A., Jang, S.B., Roh, H. & Park, K. Development of a pharmacokinetic interaction model for co-Administration of simvastatin and amlodipine. Drug Metab. Pharmacokinet.; doi.org/10.2133/dmpk. DMPK-13-RG-053.
24. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001)
25. Mangoni, A.A. & Jackson, S.H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br. J. Clin. Pharmacol. 57, 6-14 (2004)
26. Cheng, H. et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. 9, 1629-1633 (1992)
27. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005)
28. Tomita, Y., Maeda, K. & Sugiyama, Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin. Pharmacol. Ther. 94, 37-51 (2013)
29. Knauer, M.J. et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ. Res. 106, 297-306 (2010)
30. Grube, M. et al. Organic anion transporting polypeptide 2B1 is a high-Affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80, 607-620 (2006)
31. Nies, A. et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5, 1 (2013)
32. Klein, K. et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91, 1044-1052 (2012)
33. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011)
34. Li, J. et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab. Dispos. 39, 1196-1202 (2011)
35. Zhou, Q. et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol. 59, 415-424 (2005)
36. Ribbing, J. & Jonsson, E.N. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J. Pharmacokinet. Pharmacodyn. 31, 109-134 (2004)
37. Bertrand, J., Comets, E. & Mentre, F. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J. Biopharm. Stat. 18, 1084-1102 (2008)
38. Bertrand, J., Comets, E., Laffont, C.M., Chenel, M. & Mentré, F. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J. Pharmacokinet. Pharmacodyn. 36, 317-339 (2009)
39. Tsamandouras, N., Rostami-Hodjegan, A. & Aarons, L. Combining the bottom-up and top-down approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br. J. Clin. Pharmacol.; doi: 10.1111/bcp.12234.
40. Tsamandouras, N., Galetin, A., Dickinson, G., Hall, S., Rostami-Hodjegan, A. & Aarons, L. A mechanistic population pharmacokinetic model for simvastatin and its active metabolite simvastatin acid. PAGE 22nd Annual Meeting, Glasgow, Scotland, 11-14 June 2013. Abstr 2739 http://www.page-meeting. org/?abstract=2739.
41. Beal, S.L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481-504 (2001)
42. Lehr, T., Schaefer, H.G. & Staab, A. Integration of high-Throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenet. Genomics 20, 442-450 (2010)
43. Bertrand, J. & Balding, D.J. Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models. Pharmacogenet. Genomics 23, 167-174 (2013)